KK

Krutika Kishanrao Salunkhe

Active Director Director DIN 11129267
DIN 11129267 First appointment May 2025
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since May 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Krutika Kishanrao Salunkhe

Data last updated:

Krutika Kishanrao Salunkhe is a Director at Bhalkeshwar Pharma Private Limited (since 2025).

DIN 11129267
Primary Designation Director
First Appointment 28 May 2025
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Bhalkeshwar Pharma Private Limited U46497KA2025PTC203459
Director28 May 20252025Active

Directorship timeline

Open interactive timeline →
Bhalkeshwar Pharma Private Limited
Premium access

Shareholding and investment profile for Krutika Kishanrao Salunkhe

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Krutika Kishanrao Salunkhe

Krutika Kishanrao Salunkhe currently holds 1 directorship: Bhalkeshwar Pharma Private Limited (Director, since 28 May 2025).

Krutika Kishanrao Salunkhe was first appointed on 28 May 2025 as Director at Bhalkeshwar Pharma Private Limited.

The current boards of Krutika Kishanrao Salunkhe's companies include Amar Tukade (Bhalkeshwar Pharma Private Limited), Namrata (Bhalkeshwar Pharma Private Limited), Neeta Vinayakrao Shinde (Bhalkeshwar Pharma Private Limited), Prashant Narsingrao Biradar (Bhalkeshwar Pharma Private Limited), Umesh Bhalke (Bhalkeshwar Pharma Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available